Details for New Drug Application (NDA): 204024
✉ Email this page to a colleague
NDA 204024 describes FOSAMPRENAVIR CALCIUM, which is a drug marketed by Mylan and Sun Pharm and is included in two NDAs. It is available from two suppliers. Additional details are available on the FOSAMPRENAVIR CALCIUM profile page.
The generic ingredient in FOSAMPRENAVIR CALCIUM is fosamprenavir calcium. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the fosamprenavir calcium profile page.
The generic ingredient in FOSAMPRENAVIR CALCIUM is fosamprenavir calcium. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the fosamprenavir calcium profile page.
Summary for 204024
| Tradename: | FOSAMPRENAVIR CALCIUM |
| Applicant: | Sun Pharm |
| Ingredient: | fosamprenavir calcium |
| Patents: | 0 |
Suppliers and Packaging for NDA: 204024
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| FOSAMPRENAVIR CALCIUM | fosamprenavir calcium | TABLET;ORAL | 204024 | ANDA | Sun Pharmaceutical Industries, Inc. | 63304-583 | 63304-583-01 | 100 TABLET, COATED in 1 BOTTLE (63304-583-01) |
| FOSAMPRENAVIR CALCIUM | fosamprenavir calcium | TABLET;ORAL | 204024 | ANDA | Sun Pharmaceutical Industries, Inc. | 63304-583 | 63304-583-30 | 30 TABLET, COATED in 1 BOTTLE (63304-583-30) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 700MG BASE | ||||
| Approval Date: | Nov 20, 2019 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
